SUN Pharmaceutical Industries Limited — Temozolomide Exporter Profile
Indian Pharmaceutical Exporter · #1 for Temozolomide · $15.6M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #1 Indian exporter of Temozolomide with $15.6M in export value and 311 verified shipments. SUN Pharmaceutical Industries Limited holds a 62.4% market share in Temozolomide exports across 8 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Temozolomide Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Temozolomide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BELGIUM | $4.3M | 207 | 57.2% |
| CANADA | $1.4M | 28 | 18.0% |
| BRAZIL | $654.6K | 18 | 8.7% |
| COLOMBIA | $434.5K | 11 | 5.8% |
| UNITED STATES | $425.1K | 56 | 5.6% |
| PHILIPPINES | $216.8K | 7 | 2.9% |
| HONG KONG | $100.0K | 2 | 1.3% |
| SINGAPORE | $35.3K | 1 | 0.5% |
SUN Pharmaceutical Industries Limited exports Temozolomide to 8 countries. The largest destination is BELGIUM accounting for 57.2% of SUN Pharmaceutical Industries Limited's Temozolomide shipments, followed by CANADA (18.0%) and BRAZIL (8.7%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Temozolomide from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $3.8M | 184 |
| TARO PHARMACEUTICALS INC., | CANADA | $590.9K | 12 |
| YUSEN LOGISTICS BENELUX BELGIUM KEETBERGLAAN | BELGIUM | $493.4K | 23 |
| TARO PHARMACEUTICALS INC | CANADA | $420.0K | 9 |
| LABORATORIOS LA SANTE S.A. | COLOMBIA | $256.5K | 7 |
| TARO PHARMACEUTICALS INC. | CANADA | $250.0K | 5 |
| M/S | COLOMBIA | $239.1K | 7 |
| SUN PHARMA PHILIPPINES INC. | PHILIPPINES | $216.8K | 7 |
| M/S. SUN FARMACEUTICA DO BRAZIL LTD | BRAZIL | $204.0K | 5 |
| SUN PHARMACEUTICAL INDUSTRIES,INC. | UNITED STATES | $146.5K | 19 |
SUN Pharmaceutical Industries Limited supplies Temozolomide to 28 buyers globally. The largest buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by TARO PHARMACEUTICALS INC., (CANADA) and YUSEN LOGISTICS BENELUX BELGIUM KEETBERGLAAN (BELGIUM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Temozolomide Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $21.7M worth of Temozolomide through 1,261 shipments from 133 suppliers to 90 countries, serving 250 buyers globally. SUN Pharmaceutical Industries Limited contributes $15.6M to this total, accounting for 62.4% of India's Temozolomide exports. SUN Pharmaceutical Industries Limited ships Temozolomide to 8 countries through 28 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Temozolomide Exports?
SUN Pharmaceutical Industries Limited's average Temozolomide shipment value is $50.2K per consignment, based on 311 shipments totaling $15.6M. The largest destination is BELGIUM (57.2% of SUN Pharmaceutical Industries Limited's Temozolomide exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Temozolomide Exporters?
SUN Pharmaceutical Industries Limited ranks #1 among 133 Indian Temozolomide exporters with a 62.4% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($14.7M), JODAS EXPOIM PRIVATE LIMITED ($1.8M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($1.7M). SUN Pharmaceutical Industries Limited processed 311 shipments to 8 destination countries.
What Temozolomide Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TARO-TEMOZOLOMIDE 20MG CAPSULES [8050 PACK X 1X5] BATCH NO. HAF0556A MFG. DT. 03/2024 EXP. DT. 02/2026 | $150.0K | 3 |
| TARO-TEMOZOLOMIDE 100MG CAPSULES [16414PACK X 1X5] BATCH NO. HAF0558A & HAF0559A MFG. DT. 02/2024 EXP. DT. 01/2026 | $150.0K | 3 |
| TARO-TEMOZOLOMIDE 140MG CAPSULES [8307 PACK X 1X5] BATCH NO. HAF0730A & HAF0731AMFG DT: 03/2024 EXP DT: 02/2026 | $150.0K | 3 |
| TEMOZOLOMIDE SUN CAP 250MG 1x5B HU PACK | $144.0K | 3 |
| TARO-TEMOZOLOMIDE 5MG CAPSULES [25247 PACK X 1X5] BATCH NO. HAF0382B MFG. DT. 02/2024 EXP. DT. 01/2026 | $140.9K | 3 |
| TEMOZOLOMIDE SUN CAP 140MG 1x5B GB PACK | $101.7K | 4 |
| TARO-TEMOZOLOMIDE 140 MG CAPSULE BATCH : | $100.0K | 2 |
| TEMOZOLOMIDE SUN CAP 100MG 1x5B HU PACK | $100.0K | 2 |
| TARO-TEMOZOLOMIDE 20MG CAPSULES (8564 PACK X 1X5) (BATCH NO. HAF3045A MFG DT. 01/2025 EXP DT. 12/2026) | $100.0K | 2 |
| TEMOZOLOMIDE SUN CAP 100MG 1x5B IT PACK | $96.8K | 4 |
SUN Pharmaceutical Industries Limited exports 265 distinct Temozolomide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TARO-TEMOZOLOMIDE 20MG CAPSULES [8050 PACK X 1X5] BATCH NO. with 3 shipments worth $150.0K.
Regulatory Requirements: Exporting Temozolomide to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Temozolomide to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Temozolomide Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $14.7M | 311 | 8 | $47.1K |
| 3 | JODAS EXPOIM PRIVATE LIMITED | $1.8M | 35 | 5 | $50.0K |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $1.7M | 100 | 14 | $16.7K |
SUN Pharmaceutical Industries Limited ranks #1 among 133 Indian Temozolomide exporters. Average shipment value of $47.1K compared to the market average of $163.4K. The closest competitors by value are JODAS EXPOIM PRIVATE LIMITED and RELIANCE LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Temozolomide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 247 | 19.6% |
| SAHAR AIR | 221 | 17.5% |
| NHAVA SHEVA SEA (INNSA1) | 112 | 8.9% |
| DELHI AIR CARGO ACC (INDEL4) | 99 | 7.9% |
| DELHI AIR | 72 | 5.7% |
| JNPT/ NHAVA SHEVA SEA | 53 | 4.2% |
| Bombay Air | 51 | 4.0% |
| HYDERABAD ACC (INHYD4) | 50 | 4.0% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Temozolomide Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Temozolomide, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Temozolomide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Temozolomide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 330 individual customs records matching SUN Pharmaceutical Industries Limited exporting Temozolomide, covering 265 formulations to 8 countries via 28 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 90+ countries, 250+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Temozolomide Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Temozolomide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Temozolomide Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Temozolomide. For current shipment-level data, contact TransData Nexus.